Navigation Links
U of MN study shows link between gene variations and cancer survival
Date:10/22/2008

Scientific research shows that certain genes can influence a person's likelihood to contract particular diseases, cancer for example. New research at the Masonic Cancer Center, University of Minnesota demonstrates that genetic markers may also show a person's likelihood to survive the disease.

A research study led by Brian Van Ness, Ph.D., has successfully identified combinations of genes associated with early clinical relapse of multiple myeloma, a cancer of the white blood cells that produce antibodies. These results raise the possibility that a patient's genetic background exerts an important influence on the patient's prognosis and response to treatment.

"Ultimately, the goal of this research is to predict drug efficacy and toxicity based on a patient's genetic profile, and develop individualized assessments and predictions for the right drug, at the right dose, for the right patient," Van Ness said. This approach offers the dual benefits of avoiding unnecessary treatment for patients less likely to respond to a particular drug, and targeting treatments to those who will benefit most.

The findings are reported in the current issue of the research journal BMC Medicine. Van Ness heads the University's Department of Genetics, Cell Biology, and Development, and conducts research through the Masonic Cancer Center.

In this study, Van Ness and his colleagues used genetic information that the International Myeloma Foundation has gathered from myeloma patients worldwide through its program, Bank On A Cure. This first-of-its-kind program involves several of the major treatment and research centers for myeloma worldwide and thousands of myeloma patients who donate DNA samples to the bank. The University of Minnesota houses one of the program's two DNA banks (the other is in London), and Van Ness is co-director of the program.

"Although myeloma is considered a fatal disease, individual patients have widely varied rates of disease progression and response to treatment because of attributes encoded in their DNA," Van Ness said.

According to Van Ness, the research study findings demonstrate that cancer outcomes differ because patients vary in the ways they absorb, distribute, metabolize, and transport drugs across cell membranes. Individual variations in genes that regulate these biologic processes may not only affect the effectiveness of the drug, but also can result in adverse side effects.

The findings from this study pave the way for similar investigations into other cancers, neurological and cardiovascular conditions, organ transplants, and other diseases.


'/>"/>

Contact: Sara Martin
buss@umn.edu
612-626-7037
University of Minnesota
Source:Eurekalert

Related biology news :

1. NOAA and NSF commission national study of ocean acidification
2. Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators
3. New CU-Boulder study shows diversity decreases chances of parasitic disease
4. UCSF Fresno leading-edge study lends hope to emphysema patients
5. Study sheds new light on dolphin coordination during predation
6. Current mass extinction spurs major study of which plants to save
7. Study: Wildlife need more complex travel plans
8. UGA study reveals ecosystem-level consequences of frog extinctions
9. Study links nicotine with breast cancer growth and spread
10. Study finds high mortality of endangered loggerhead sea turtles in Baja California
11. Landmark study unlocks stem cell, DNA secrets to speed therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2016)... India , March 11, 2016 ... a new market research report "Image Recognition Market by ... Application (Marketing and Advertising), by Deployment Type (On-Premises and ... Forecast To 2022", published by MarketsandMarkets, the global market ... 2015 to USD 29.98 Billion by 2020, at a ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
Breaking Biology News(10 mins):
(Date:5/5/2016)... ... May 05, 2016 , ... ... has granted two additional patents, U.S. Patent Nos. 9,322,133 and 9,322,134, to API ... for making nanocellulose as well as hydrophobic nanocellulose compositions. In addition to ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences (“ProMIS” ... first three targets, it has identified a fourth in a series of novel ... development and progression of Alzheimer’s disease (AD). , “This discovery is ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering everything from gourmet cooking ... an experience she won’t forget. , Guests that visit LaJollaCooks4u share an experience ...
(Date:5/4/2016)... 4, 2016  Bayer today announced that a ... ® (regorafenib) tablets for the treatment of ... its primary endpoint of a statistically significant improvement ... the efficacy and safety of regorafenib in patients ... with sorafenib. The safety and tolerability were generally ...
Breaking Biology Technology: